These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 34064698)
21. Inhalation Dosage Forms: A Focus on Dry Powder Inhalers and Their Advancements. Magramane S; Vlahović K; Gordon P; Kállai-Szabó N; Zelkó R; Antal I; Farkas D Pharmaceuticals (Basel); 2023 Nov; 16(12):. PubMed ID: 38139785 [TBL] [Abstract][Full Text] [Related]
22. Development of a Carrier Free Dry Powder Inhalation Formulation of Ketotifen for Pulmonary Drug Delivery. Azari F; Ghanbarzadeh S; Safdari R; Yaqoubi S; Adibkia K; Hamishehkar H Drug Res (Stuttg); 2020 Jan; 70(1):26-32. PubMed ID: 31533157 [TBL] [Abstract][Full Text] [Related]
23. "Pierce and inhale" design in capsule based dry powder inhalers: Effect of capsule piercing and motion on aerodynamic performance of drugs. Martinelli F; Balducci AG; Rossi A; Sonvico F; Colombo P; Buttini F Int J Pharm; 2015 Jun; 487(1-2):197-204. PubMed ID: 25843756 [TBL] [Abstract][Full Text] [Related]
24. [Stability testing of meloxicam-containing microcomposites for inhalation]. Pomázi A; Ambrus R; Szabóné Révész P Acta Pharm Hung; 2014; 84(2):55-62. PubMed ID: 25167700 [TBL] [Abstract][Full Text] [Related]
25. Development of a dry powder inhaler, the Ultrahaler, containing triamcinolone acetonide using in vitro-in vivo relationships. Lim JG; Shah B; Rohatagi S; Bell A Am J Ther; 2006; 13(1):32-42. PubMed ID: 16428920 [TBL] [Abstract][Full Text] [Related]
26. Supercritical Fluid Particle Design of DPI Formulations (Review). Sun Y Curr Pharm Des; 2015; 21(19):2516-42. PubMed ID: 25876911 [TBL] [Abstract][Full Text] [Related]
27. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. Adi H; Young PM; Chan HK; Agus H; Traini D Eur J Pharm Sci; 2010 Jun; 40(3):239-47. PubMed ID: 20371286 [TBL] [Abstract][Full Text] [Related]
28. Investigation of Electrostatic Behavior of Dry Powder-Inhaled Model Formulations. Jetzer MW; Morrical BD J Pharm Sci; 2019 Sep; 108(9):2949-2963. PubMed ID: 31004652 [TBL] [Abstract][Full Text] [Related]
29. Applications of capsule dosing techniques for use in dry powder inhalers. Edwards D Ther Deliv; 2010 Jul; 1(1):195-201. PubMed ID: 22816126 [TBL] [Abstract][Full Text] [Related]
30. Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach. Karimi K; Pallagi E; Szabó-Révész P; Csóka I; Ambrus R Drug Des Devel Ther; 2016; 10():3331-3343. PubMed ID: 27784991 [TBL] [Abstract][Full Text] [Related]
31. Performance qualification of a new hypromellose capsule: part I. Comparative evaluation of physical, mechanical and processability quality attributes of Vcaps Plus, Quali-V and gelatin capsules. Sherry Ku M; Li W; Dulin W; Donahue F; Cade D; Benameur H; Hutchison K Int J Pharm; 2010 Feb; 386(1-2):30-41. PubMed ID: 19900518 [TBL] [Abstract][Full Text] [Related]
32. [Powder modificationfor improving content uniformity of Ziyin Yiwei Capsules]. Chen ZZ; Yang RP; Shi YJ; Jia XB; Guo DY; Zou JB; Feng L; Zhao ZP Zhongguo Zhong Yao Za Zhi; 2021 Dec; 46(23):6053-6061. PubMed ID: 34951232 [TBL] [Abstract][Full Text] [Related]
33. Formulation development of inhalation powders for FK888 using the E-haler to improve the inhalation performance at a high dose, and its absorption in healthy volunteers. Nakate T; Yoshida H; Ohike A; Tokunaga Y; Ibuki R; Kawashima Y Eur J Pharm Biopharm; 2005 Jan; 59(1):25-33. PubMed ID: 15567298 [TBL] [Abstract][Full Text] [Related]
34. Bioavailability and in vitro oesophageal sticking tendency of hydroxypropyl methylcellulose capsule formulations and corresponding gelatine capsule formulations. Honkanen O; Laaksonen P; Marvola J; Eerikäinen S; Tuominen R; Marvola M Eur J Pharm Sci; 2002 Jun; 15(5):479-88. PubMed ID: 12036724 [TBL] [Abstract][Full Text] [Related]
35. Dose administration maneuvers and patient care in tobramycin dry powder inhalation therapy. Buttini F; Balducci AG; Colombo G; Sonvico F; Montanari S; Pisi G; Rossi A; Colombo P; Bettini R Int J Pharm; 2018 Sep; 548(1):182-191. PubMed ID: 29883795 [TBL] [Abstract][Full Text] [Related]
36. Discrete Element Method Evaluation of Triboelectric Charging Due to Powder Handling in the Capsule of a DPI. Alfano FO; Di Renzo A; Di Maio FP Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376210 [TBL] [Abstract][Full Text] [Related]
37. The role of particle properties in pharmaceutical powder inhalation formulations. Chew NY; Chan HK J Aerosol Med; 2002; 15(3):325-30. PubMed ID: 12396421 [TBL] [Abstract][Full Text] [Related]
38. Formulation techniques for high dose dry powders. Brunaugh AD; Smyth HDC Int J Pharm; 2018 Aug; 547(1-2):489-498. PubMed ID: 29778822 [TBL] [Abstract][Full Text] [Related]
39. Fragmented particles containing octreotide acetate prepared by spray drying technique for dry powder inhalation. Hou A; Li L; Huang Y; Singh V; Zhu C; Pan X; Quan G; Wu C Drug Deliv Transl Res; 2018 Jun; 8(3):693-701. PubMed ID: 29600480 [TBL] [Abstract][Full Text] [Related]
40. Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler. Young PM; Crapper J; Philips G; Sharma K; Chan HK; Traini D J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):138-47. PubMed ID: 24004178 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]